Business Context and Reporting Period
Company: Aquestive Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 9, 2024
Purpose: Disclosure of investor presentations under Regulation FD (Item 7.01). The filing serves to disseminate information presented to institutional investors and analysts, specifically a corporate presentation and a presentation delivered at the H.C. Wainwright 26th Annual Global Investor Conference.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to attach investor presentations (Exhibits 99.1 and 99.2) rather than a financial statement report containing audited or unaudited financial data.
Material Changes
No material changes to financial performance or operations are detailed within the text of this Form 8-K. The filing references the availability of updated information in the attached exhibits, which may contain forward-looking statements or strategic updates, but the 8-K text itself does not quantify changes versus prior periods.
Guidance, Outlook, and Risks
- Management Commentary: The Company provided presentations to investors on September 9, 2024. The text notes that the information in these presentations may be amended or updated at any time.
- Forward-Looking Statements: The filing explicitly states that the information in Item 7.01 and the attached exhibits shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
- Risks: The text does not list specific risk factors but directs readers to the attached exhibits for the full context of the investor communications.
Investor Verification Checklist
- Review Exhibit 99.1 (Corporate Presentation dated September 2024) for detailed business updates.
- Review Exhibit 99.2 (H.C. Wainwright Conference Presentation) for specific commentary provided on September 9, 2024.
- Verify the availability of these documents on the Company's website (www.aquestive.com), noting the Company reserves the right to discontinue availability.
- Confirm that any forward-looking statements in the exhibits are not considered "filed" under the Exchange Act unless specifically referenced in a subsequent filing.